Immunovant, Inc. (IMVT)
NASDAQ: IMVT · Real-Time Price · USD
21.27
+0.82 (4.01%)
At close: Feb 21, 2025, 4:00 PM
21.35
+0.08 (0.38%)
After-hours: Feb 21, 2025, 7:49 PM EST
Immunovant Employees
Immunovant had 207 employees as of March 31, 2024. The number of employees increased by 43 or 26.22% compared to the previous year.
Employees
207
Change (1Y)
43
Growth (1Y)
26.22%
Revenue / Employee
n/a
Profits / Employee
-$1,848,841
Market Cap
3.61B
Employees Chart
Related Stocks
| Company Name | Employees |
|---|---|
| UnitedHealth Group | 440,000 |
| Johnson & Johnson | 131,900 |
| Thermo Fisher Scientific | 122,000 |
| Abbott Laboratories | 114,000 |
| AstraZeneca | 89,900 |
| Novo Nordisk | 77,349 |
| Novartis AG | 75,883 |
| Merck & Co. | 72,000 |
IMVT News
- 16 days ago - Immunovant Reports Financial Results for the Quarter Ended December 31, 2024 - GlobeNewsWire
- 4 weeks ago - Kuehn Law Encourages Investors of Immunovant, Inc. to Contact Law Firm - PRNewsWire
- 2 months ago - Immunovant: Continued FcRn Targeting With IMVT-1402 Pivotal Study - Seeking Alpha
- 2 months ago - FcRn Inhibitor Market Size, Target Population, Competitive Landscape & Forecast to 2034 - Immunovant Advances FcRn Inhibitor Pipeline with Promising Results and FDA Green Light for Pivotal Trial - GlobeNewsWire
- 3 months ago - Immunovant Provides Development Updates and Reports Financial Results for the Quarter Ended September 30, 2024 - GlobeNewsWire
- 4 months ago - Immunovant Announces Oral Presentation of Late Breaking Abstract for Phase 2 Graves' Disease Clinical Data at the 2024 American Thyroid Association (ATA) Annual Meeting - GlobeNewsWire
- 5 months ago - Top 2 Health Care Stocks That May Collapse This Quarter - Benzinga
- 5 months ago - Immunovant Provides Update on Graves' Disease Development Program - GlobeNewsWire